Antibody therapeutics for Ebola virus disease

Larry Zeitlin, Kevin J. Whaley, Gene G. Olinger, Michael Jacobs, Robin Gopal, Xiangguo Qiu, Gary P. Kobinger

Research output: Contribution to journalReview articlepeer-review


With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.

Original languageEnglish (US)
Pages (from-to)45-49
Number of pages5
JournalCurrent Opinion in Virology
StatePublished - Apr 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Antibody therapeutics for Ebola virus disease'. Together they form a unique fingerprint.

Cite this